Details for: NEUPOGEN
Company: AMGEN CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 01968017 | NEUPOGEN | FILGRASTIM | 300 MCG / ML | SOLUTION | INTRAVENOUS |
| 01968017 | NEUPOGEN | FILGRASTIM | 300 MCG / ML | SOLUTION | SUBCUTANEOUS |
| 02420104 | NEUPOGEN | FILGRASTIM | 600 MCG / ML | SOLUTION | INTRAVENOUS |
| 02420112 | NEUPOGEN | FILGRASTIM | 600 MCG / ML | SOLUTION | INTRAVENOUS |
| 02420104 | NEUPOGEN | FILGRASTIM | 600 MCG / ML | SOLUTION | SUBCUTANEOUS |
| 02420112 | NEUPOGEN | FILGRASTIM | 600 MCG / ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Summary Safety Review - NEUPOGEN (filgrastim) and NEULASTA (pegfilgrastim) - Capillary Leak Syndrome
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.